Case GI SPORE

本Case Gl SPORE提案为胃肠道恶性肿瘤的卓越研究提供了一个前沿的专业项目，重点是结肠直肠癌和额外关注食道腺癌。这个综合项目以Case综合癌症中心的资源为基础，提出4个转化研究项目，为Gl癌症患者带来新的分子进展。一系列的4个核心资源支持这些研究项目，并为Gl癌症的转化研究建立了强大的规划基础设施。我们进一步开发了一个全面的基础设施，用于从凯斯癌症中心的基础科学和临床研究人员那里确定新的发展研究项目。此外，根据我们在培养强调Gl癌症转化研究的新教师方面的良好记录，我们提出了一个有针对性的职业发展计划，以进一步加强SPORE教师的转化研究骨干。4个SPORE转化研究项目构成了Gl癌症的新颖和前沿方法，包括：新的15-PGDH结肠癌抑制途径的预测、预后和治疗应用研究(项目1，dr。马科维茨和威尔逊)；通过粪便DNA甲基化检测晚期结肠腺瘤的无创早期检测(项目2，dr。库珀和李)；通过使用高通量下一代基因组测序，对结肠癌基因突变作为临床预后预测因子的综合评估(项目3，dr。威利斯和王)；以及食管腺癌易感基因的鉴定(项目4，dr。Chak和Elston)。这些项目得益于我们的SPORE教师开发的特殊人群和科学资源：结肠癌生物标志物的评估，新药发现的高通量筛选，结肠癌筛查方式的评估，福尔马林固定组织样本的下一代测序，以及家族性巴雷特癌和食管腺癌的研究。这些调查人员的力量和他们掌握的资源将确保该计划取得重要进展。

This Case Gl SPORE proposal provides for a cutting edge Specialized Program of Research Excellence in gastrointestinal malignancies with emphasis on colorectal cancers and with additional attention to adenocarcinoma of the esophagus. This comprehensive program builds on the resources of the Case Comprehensive Cancer Center to propose 4 translational Research Projects to bring new molecular advances to patients with Gl Cancers. A series of 4 core resources support these research projects and also establish a strong programmatic infrastructure for translational research in Gl cancers. We further have developed a comprehensive infrastructure for identifying new Developmental Research Projects from basic science and clinical investigators from across the Case Cancer Center. Moreover, drawing on our strong track record of developing new faculty who emphasize translational research in Gl cancers, we propose a targeted Career Development Program to further enhance the translational research cadre of SPORE faculty. The 4 SPORE translational research projects constitute novel and cutting edge approaches to Gl cancers and include studies of: the predictive, prognostic, and therapeutic applications of the new 15-PGDH colon cancer suppressor pathway (Project 1, Drs. Markowitz and Willson); the noninvasive early detection of advanced colon adenomas through stool DNA testing for methylated DNA (Project 2, Drs. Cooper and Li); the comprehensive evaluation of colon cancer gene mutations as predictors of clinical outcome, via use of high throughput Next Generation genomic sequencing (Project 3, Drs. Willis and Wang); and the identification of esophageal adenocarcinoma susceptibility genes (Project 4, Drs. Chak and Elston). These projects are advantaged by special population and scientific resources developed by our SPORE faculty for: evaluation of colon cancer biomarkers, for high throughput screening for new drug discovery, for evaluation of colon cancer screening modalities, for Next Generation sequencing from archived formalin fixed tissue samples, and for study of familial Barrett's and adenocarcinomas of the esophagus. The strength of these investigators and the resources at their disposal will ensure this program leads to important advances.